Skip to main content

Year: 2019

Tabula Rasa HealthCare Expands into a New Market with Hudson Headwaters Health Network Contract

MOORESTOWN, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare®, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces a partnership with Hudson Headwaters Health Network, a Queensbury, NY-based nonprofit that operates 19 health centers in northern New York state. Beginning in January 2020, Hudson Headwaters pharmacists will license the MedWise technology to identify patients at high risk for medication-related problems and complete Medication Safety Reviews.“TRHC’s partnership with Hudson Headwaters represents the value TRHC’s MedWise technology can provide a program with a primary focus of improving the health of an underserved population,” said TRHC Chairman and CEO, Calvin H. Knowlton, Ph.D. “Furthermore, the Federally Qualified Health Center (FQHC) market...

Continue reading

Mission Ready Provides Revenue Guidance, SOE Solicitation Update

VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) — Mission Ready Solutions Inc. (“Mission Ready” or the “Company”) (TSXV: MRS) is pleased to report a substantial increase in booked revenues for Q4 2019 – currently projected to be ~$10 million – up over 100% from the $4.9 million reported in the Q3 2019 and 1,400% over the reported revenue for the corresponding period in 2018 (Q4 2018). Revenues for October 1, 2019 through December 31, 2019 will be reflected in the Q4 2019 audited results which are due to be filed April 29, 2020.The projected increase in revenues through Q1 2021 is primarily attributable to the scheduled fulfillment of confirmed orders received by the Company through its privileged access to numerous government contracting vehicles. In a news release dated September 20, 2019, the Company reported that...

Continue reading

Virtusa Improves Field Force Worker Efficiency with Augmented Reality and AI

SOUTHBOROUGH, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) — Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT services and solutions that help clients change and disrupt markets through innovation engineering, today announced new capabilities, including augmented reality (AR) based test and diagnostic capabilities to improve the efficiency of field force workers and help them improve customer service while reducing average handling time.Traditional Communications Service Providers (CSPs), wireless providers, internet, cable, and satellite operators, along with other managed service providers, typically have a large contractor-based field force that must be trained to diagnose and make repairs using a massive portfolio of products and equipment. Virtusa’s Smart Field Force Management...

Continue reading

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

— Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 —— Supplemental cohort continues enrollment to meet patient demand —BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) —  Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced it completed enrollment of the pivotal cohort in its Phase 3 clinical trial evaluating setmelanotide for the treatment of insatiable hunger and severe obesity in individuals living with Bardet-Biedl syndrome (BBS) or Alström syndrome. The Company enrolled 32 individuals with BBS and six individuals with Alström syndrome in the pivotal cohort, and it will continue to enroll patients in a supplemental cohort to meet demand...

Continue reading

AgraFlora Organics procèdera à l’acquisition de 88 acres servant à la culture extérieure de cannabis et d’une installation de traitement de cannabis licenciée de 27 000 pieds carrés

VANCOUVER, Colombie-Britannique, 05 déc. 2019 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (« AgraFlora » ou la « Société ») (CSE : AGRA) (Frankfurt: PU31) (OTCPK : AGFAF) une société internationale de cannabis diversifiée et axée sur la croissance est heureuse d’annoncer qu’elle a conclu un accord provisoire (l’« accord ») en vue d’acquérir 100 % des actions émises et en circulation de Sanna Health Corp. (« Sanna ».) Sanna est une société de cannabis canadienne basée dans la région du Grand Toronto, qui bénéficie des licences suivantes, accordées en vertu du Règlement sur l’accès au cannabis à des fins médicales (« RACFM ») :une licence de culture standard ;une licence de traitement standard ; et,une licence de vente médicale.Brandon Boddy, PDG d’AgraFlora, a déclaré : « Il s’agit d’une acquisition historique pour AgraFlora....

Continue reading

Stratabound Announces Completion of Definitive Option Agreement and Commencement of Diamond Drilling on McIntyre Gold Project, as well as Renegotiation of Golden Culvert Option Agreements

TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) — Stratabound Minerals Corp. (TSXV: SB) (“Stratabound” or “the Company”) is pleased to announce it has completed the transaction for an option to acquire 100% of the mineral rights to the McIntyre Gold Project located adjacent to Highway 180 about 80 kilometres west of Bathurst, New Brunswick as previously announced November 13, 2019. Stratabound and the owner of the claims have signed a definitive option agreement which sets out the terms under which Stratabound has the right and option to earn 100% interest in the claims through cash payments, share issuances and work commitments. Stratabound issued 300,000 common shares to the owner upon signing the option agreement, and by the first anniversary of signing Stratabound has committed to complete $50,000 in exploration work at the property....

Continue reading

Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), on Monday, December 9, 2019, from 12:00 PM to 2:00 PM ET, at the American Epilepsy Society (AES) 2019 Annual Meeting in Baltimore.The event will include a discussion of new data presented at the AES conference and a Key Opinion Leader will review the evidence of long-term neurocognitive improvements associated with seizure reduction demonstrated in the FINTEPLA® clinical studies. Zogenix management team will provide updates on the ongoing expanded access program and open-label extension study with FINTEPLA and U.S. pre-launch preparation activities...

Continue reading

ICG: Total Voting Rigts

Intermediate Capital Group plc (the “Company”)5th December 2019TOTAL VOTING RIGHTSIntermediate Capital Group plc (the “Company”) has made an application for the admission of 3,412 Ordinary Shares of 26 1/4 pence each in the Company which to the Official List of the UK Listing Authority and to trading on the London Stock Exchange, in connection with the exercise of options by an employee of the Company in relation to The Intermediate Capital Group PLC Save As You Earn Plan 2004 (as amended and updated 2014). Admission of the shares to the Official list is expected to occur on 10th December 2019.The shares are issued fully paid and rank pari passu in all other respects with the existing issued Ordinary Shares of the Company.In addition, the Company wishes to notify the market (as per DTR 5.6.1R) that, as a result of the above...

Continue reading

FLEURY MICHON : Déclaration mensuelle rachat d’actions 11 2019

CONTRAT DE LIQUIDITE ET OU PROGRAMME DE RACHATTABLEAU DE DECLARATION MENSUELLE DES OPERATIONS REALISEESPAR UN EMETTEUR SUR SES PROPRES TITRESINFORMATIONS CUMULEES Nombre de titres composant le capital de l’émetteur au début du programme                4 387 757Capital auto détenu de manière directe et indirecte au début du programme (en titres + %) :…Exercice d’options attribuées aux salariés, de titres de créances donnant accès au capital A la date d’établissement de la présente déclaration Pièce jointe2019 11 Rachat Actions

Continue reading

Direct Supervision of the European Central Bank

Šiaulių Bankas AB, company code 112025254, domicile address Tilžės st. 149, LT-76348 Šiauliai, Lithuania.On 4 December 2019, the European Central Bank (ECB) published an updated list of supervised entities. Šiaulių Bankas AB was classified as significant entity directly supervised by the ECB as one of the three largest credit institutions in Lithuania.  The ECB will directly supervise the bank from 1 January 2020. Additional information:Head of Finance and Risk Management DivisionDonatas Savickas, +370 41 595 602, donatas.savickas@sb.lt

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.